

*To the Copenhagen Stock Exchange  
and the Press*

Release no. 23/2007

## **Pharmexa**

Chief Commercial Officer (CCO) Peter Nordkild has resigned his position in Pharmexa to accept the position as CEO in the Danish biotech company Egalet. Peter Nordkild's responsibilities will until further notice be taken over by Chief Executive Officer Jakob Schmidt.

Hørsholm, August 23, 2007

Jakob Schmidt  
Chief Executive Officer

### **Additional information:**

Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525

Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

**Note to editors:** *Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.*